Although the benefits of originator infliximab have been deemed to outweigh the potential harm during pregnancy, in a recent observational study, researchers looked to evaluate whether biosimilar infliximab therapy was associated with any new safety risks.
Anti-tumor necrosis factor (anti-TNF) therapy used to treat pregnant patients with inflammatory bowel disease (IBD) has been linked with lower birth weight, shorter gestational term, and in some studies, more frequent birth defects or spontaneous abortion.
Although the benefits of originator infliximab have been deemed to outweigh the potential harm during pregnancy, in a recent observational study, researchers looked to evaluate whether biosimilar infliximab therapy was associated with any new safety risks in the same population.
The observational study was conducted among 20 pregnant women who were treated with biosimilar infliximab. Researchers compiled data on disease activity, prior treatment, and newborn outcome, as well as blood levels of the anti-TNF agent.
Of the 20 women studied, 16 had Crohn disease, and 4 had ulcerative colitis. Patients’ mean age was 28.7 (±4.1), and 55% (n = 11) were pregnant for the first time.
At the time they conceived, 30% (6) of the patients had active disease, and 65% (n = 13) were in remission. One patient was newly diagnosed with acute severe colitis after having conceived. Other than the last patient, all women had already received infliximab treatment prior to pregnancy.
Researchers recorded 19 live births, with a mean weight 3305 g (±493 g), 18 of which were at term. One was both preterm and had a low birth weight. One pregnancy was spontaneously aborted.
In addition, researchers found that disease activity at conception was associated with both lower birth weight; mean birthweight was 3549 g (±392 g) in the remission group versus 2921 g (±390 g) in the active disease group, respectively (P =.0043).
Although researchers note that findings were limited by the small study size, no new safety concerns were found in pregnant women treated with biosimilar infliximab. In addition, according to the study authors, this was the first report of pregnancy outcomes in women treated with biosimilar infliximab.
Reference
Kolar M, Duricova D, Bortlik M, et al. Pregnancy outcomes in women with IBD treatment with biosimilar infliximab. Presented at the European Crohn's and Colitis Organisation Congress 2018 meeting, February 14-17, 2018; Vienna, Austria. Abstract P614.
ecco-ibd.eu/publications/congress-abstract-s/abstracts-2018/item/p614-pregnancy-outcomes-in-women-with-ibd-treated-with-biosimilar-infliximab.html
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 7th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.